Autolus Therapeutics announced that Dr. Lucinda Crabtree has provided notice of her resignation as CFO of the Company to pursue a new opportunity. Dr Crabtree will remain with the Company until Q3, 2023 in order to ensure a smooth and orderly transition. Autolus has initiated a formal search process for the selection of a new CFO.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AUTL:
- Autolus Therapeutics announces resignation of Chief Financial Officer
- Autolus Therapeutics reports no business relationship with Silicon Valley Bank
- Autolus Therapeutics price target lowered to $12 from $18 at Mizuho
- Autolus Therapeutics reports FY22 EPS ($1.57), consensus ($1.58)
- Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
